文献速递泌尿男性生殖肿瘤支持与姑息治疗

奥拉帕利联合镭-223对比镭-223治疗转移性去势抵抗性前列腺癌骨转移的随机II期试验

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
PubMed 文献 · J Clin Oncol · 2026-05-07

这项多中心随机II期试验纳入120例转移性去势抵抗性前列腺癌(mCRPC)伴骨转移患者,比较奥拉帕利联合镭-223与单用镭-223的疗效与安全性。联合组显著延长研究者评估的影像学无进展生存期(rPFS),中位8.9个月对比4.7个月,风险比0.50。联合组≥3级治疗相关不良事件发生率更高(56%对比33%),主要为血液学毒性,但总体可管理。

要点

  • 奥拉帕利联合镭-223显著改善mCRPC骨转移患者的rPFS(8.9对比4.7个月,HR 0.50)。
  • 未接受过多西他赛和骨转移灶≤20个的患者获益更明显。
  • 联合组≥3级血液学毒性增加,但总体可管理。

核心结论

  • 在mCRPC伴骨转移男性中,奥拉帕利联合镭-223较单用镭-223显著延长研究者评估的rPFS。
  • 联合方案虽增加血液学毒性,但总体可管理,支持进一步探索DNA损伤靶向策略。

研究设计与样本

  • 多中心、随机、II期试验,纳入120例mCRPC且≥2处骨转移的男性,1:1随机分配至奥拉帕利(200 mg每日两次)联合镭-223(55 kBq/kg静脉注射,每4周一次×6剂)或单用镭-223,允许进展后交叉。
  • 主要终点为研究者评估的影像学无进展生存期(rPFS)。

主要发现

  • 未接受过多西他赛患者中位rPFS 13.7个月对比5.7个月,HR 0.24(90%CI 0.15-0.40)。
  • 骨转移灶≤20个患者中位rPFS 13.4个月对比4.2个月,HR 0.21(90%CI 0.13-0.33)。
  • 联合组1年症状性骨骼相关事件累积发生率更低(12.7%对比22.9%)。
  • 中位总生存期两组相似(20.2个月对比21.1个月)。

关键数值与推荐

  • 联合组≥3级治疗相关不良事件发生率56%,单用镭-223组33%。
  • 血液学毒性包括淋巴细胞减少(31%对比9.1%)、贫血(22%对比16%)、血小板减少(6.8%对比3.6%)。
  • 入组患者中96%曾接受雄激素受体通路抑制剂,52%曾接受多西他赛,47%骨转移灶>20个,90%使用骨保护剂。

临床怎么用

  • 对于mCRPC伴骨转移、尤其未接受过多西他赛或骨转移灶负荷较低的患者,可考虑奥拉帕利联合镭-223以延长rPFS。
  • 联合治疗需密切监测血液学毒性,包括淋巴细胞减少、贫血和血小板减少。

局限性

  • 为II期试验,样本量120例,总生存期未见显著差异,需进一步验证。
  • 主要终点为研究者评估的rPFS,非盲态设计可能引入评估偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radium-223 is an α-emitting radiopharmaceutical that improves survival in metastatic castration-resistant prostate cancer (mCRPC). Preclinical data suggest synergy between poly(ADP-ribose) polymerase (PARP) inhibition and radiation. After phase I dose-finding, we conducted a randomized phase II trial to assess efficacy and safety of this combination versus radium-223. PATIENTS AND METHODS: Men with mCRPC and ≥2 bone metastases (BM) were randomly assigned 1:1 to olaparib (200 mg twice daily) plus radium-223 (55 kBq/kg intravenous once every 4 weeks × 6 doses) or radium-223. Crossover was allowed at progression. The primary end point was investigator-assessed radiographic progression-free survival (rPFS). RESULTS: A total of 120 patients were randomly assigned. Most had prior androgen receptor pathway inhibitor exposure (96%), 52% had received docetaxel, 47% had >20 BM, and 90% received bone-protecting agents. The combination significantly improved rPFS (median 8.9 v 4.7 months; hazard ratio [HR], 0.50 [one-sided 90% CI, 0.35 to 0.70]; one-sided P = .0042). The benefit was most pronounced in patients without prior docetaxel (13.7 v 5.7 months; HR, 0.24 [90% CI, 0.15 to 0.40]) and those with ≤20 BM (13.4 v 4.2 months; HR, 0.21 [90% CI, 0.13 to 0.33]). The 1-year cumulative incidence of symptomatic skeletal-related events was lower with the combination (12.7% v 22.9%). Median overall survival was similar (20.2 v 21.1 months). Grade ≥3 treatment-related adverse events occurred in 56% versus 33% (combination v radium-223), primarily hematologic, including lymphopenia (31% v 9.1%), anemia (22% v 16%), and thrombocytopenia (6.8% v 3.6%). CONCLUSION: Olaparib plus radium-223 significantly prolonged rPFS compared with radium-223 in men with mCRPC and BM. Despite increased hematologic toxicity, the regimen was manageable and supports further exploration of DNA damage-targeted strategies in this population.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McKay RR, Xie W, Ajmera A, et al. Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). J Clin Oncol. 2026. PMID: 42096662. doi:10.1200/JCO-25-02835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。